All,

As we look to the future and build our business above and beyond where we are today we are also changing the tagline of the company to reflect a bigger, broader view that further enforces and illustrates where we are headed.  All part of thinking BIG!  Special thanks to the Executive Team as well as the Marketing Team in helping think through this new tagline.

Drum roll………;)!

Our new tagline will be Innovations For Active Healing which will replace Active Healing Through Orthobiologics over the coming months.

Here are some key points on this decision as well as next steps.

  • We believe this new phrase more accurately describes our entire portfolio and potential future tuck in acquisitions. “Orthobiologics” often gets confused on what exactly it represents as it is defined many ways by many different people, industry leaders and market reports.  We are hard pressed to define our HA products, Exogen and our bone graft substitutes all as Orthobiologics but they are ALL Innovations for Active Healing!
  • This will marry well with our three verticals in how we speak to the outside world about Bioventus; HA/Sports Medicine, MI Fracture Treatment/Exogen and Bone Graft Substitutes.  These areas cross the spectrum of orthopedics from a customer standpoint and will provide a leverage point for further growth into new areas.
  • The Bone Graft Substitutes vertical otherwise known as the Surgical business will continue to use the term “Orthobiologics” as a descriptor for their products where it most closely fits.
  • We have already made these changes to the new corporate website www.Bioventus.com and to Bionet.
  • Moving forward Scott Petrie and his Creative Services team will begin making changes on sales collateral pieces, product websites, PPT templates, letterhead and other locations where the old tagline appears.
  • You will hear more about changes to items like business cards in Q1 2021.
  • We expect this to take some time and all changes are scheduled to be completed around the end of summer 2021.
  • We will also change our Corporate Vision to Global Leader in Innovations for Active Healing reflecting our strong mission of serving patients and returning them to active and healthy lives!

We also achieved a BIG milestone this week as the IND for Motys was submitted on time per our corporate objectives!  Well done to Alessandra for her vision and leadership as well as the direct management of MK Kottke on this very complex project.  Below is a great list MK put together on the scope of the IND and the many contributions from this stellar team!

Bioventus has successfully “delivered” its first ever Investigational New Drug Application!

134 documents | 2,654 hyperlinks | 3,629 pages | 158 eCTD-specific validation criteria

This accomplishment by our small, but highly engaged and talented team, is traditionally supported by a large team of tenured biopharma experts.

Please join me in acknowledging the outstanding contributions of this team, including:

Carl Flannery – Our expert in OA. Directed, developed, and guided all pre-clinical data supporting this IND (i.e., 95% of the aforementioned documents)

Neill Pounder – General team / data wrangler, reviewer, and sounding board.

John Rice – Calmly and efficiently managed all authoring. Orchestrated the creation, publication, and QC of the eCTD-compliant submission.

Scott Seaman – A non-stop writing machine. Report writing and document creation is a laborious process for any scientist, but his drive was impressive.

Kelly Buddin – Another writing machine. Her attention to detail has been key through individual document creation and final QC of the publication.

Drew Sullivan – Quietly worked in the background to operationalize the clinical trial for our IND. Winding back to November of last year, Drew also “volunteered” to operationalize our IND-enabling toxicology study.

Jonathan Han – Developed the quality systems to support of very first clinical trial under an IND – no mean feat for this medical device company!

Jason Siegfried – Countless reviews and patience to confirm our understanding of MTF Biologic’s manufacturing processes.

Peter Shaw – Thoughtful review and approval of the underpinning clinical trial protocol.

Nicole Sgherza – Instant response to any and all requests to procure literature and ensure that our citation tools were working effectively.

Thank you all and thank you Alessandra and MK for hitting your goal!

Lastly, no one is BIGGER in this day and age then Dr. Fauci who has been a global leader during the pandemic.  Bioventus is proud to sponsor honoring Dr. Fauci at the upcoming National Italian American Foundation where he will be sole honoree on October 31st.  Thank you to Tom Hill and Scott Petrie for developing this ad that highlights are new Innovations for Active Healing tagline!

Have a healthy, safe and terrific Fall weekend!

Best Regards,

Ken